DE602004013554D1 - Verbindungen und verfahren zur diagnose von prostatakrebs - Google Patents

Verbindungen und verfahren zur diagnose von prostatakrebs

Info

Publication number
DE602004013554D1
DE602004013554D1 DE602004013554T DE602004013554T DE602004013554D1 DE 602004013554 D1 DE602004013554 D1 DE 602004013554D1 DE 602004013554 T DE602004013554 T DE 602004013554T DE 602004013554 T DE602004013554 T DE 602004013554T DE 602004013554 D1 DE602004013554 D1 DE 602004013554D1
Authority
DE
Germany
Prior art keywords
prostate cancer
diagnosis
compounds
methods
determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004013554T
Other languages
English (en)
Inventor
Nathan Karin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rappaport Family Institute for Research in the Medical Sciences
Original Assignee
Rappaport Family Institute for Research in the Medical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rappaport Family Institute for Research in the Medical Sciences filed Critical Rappaport Family Institute for Research in the Medical Sciences
Publication of DE602004013554D1 publication Critical patent/DE602004013554D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE602004013554T 2003-03-12 2004-03-14 Verbindungen und verfahren zur diagnose von prostatakrebs Expired - Lifetime DE602004013554D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45351503P 2003-03-12 2003-03-12
US45351403P 2003-03-12 2003-03-12
US52513503P 2003-11-28 2003-11-28
US53411104P 2004-01-05 2004-01-05
PCT/IL2004/000240 WO2004080273A2 (en) 2003-03-12 2004-03-14 Compositions and methods for diagnosing and treating prostate cancer

Publications (1)

Publication Number Publication Date
DE602004013554D1 true DE602004013554D1 (de) 2008-06-19

Family

ID=32996377

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004013554T Expired - Lifetime DE602004013554D1 (de) 2003-03-12 2004-03-14 Verbindungen und verfahren zur diagnose von prostatakrebs

Country Status (5)

Country Link
US (2) US7749714B2 (de)
EP (1) EP1601682B1 (de)
AT (1) ATE394676T1 (de)
DE (1) DE602004013554D1 (de)
WO (1) WO2004080273A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1601682B1 (de) 2003-03-12 2008-05-07 Rappaport Family Institute For Research in the Medical Sciences Verbindungen und verfahren zur diagnose von prostatakrebs
US8017113B2 (en) 2003-03-12 2011-09-13 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
WO2007021807A1 (en) 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
EP1989216A4 (de) * 2006-03-01 2010-03-31 Univ Michigan Diagnose und behandlung von prostatakrebs
WO2009088992A2 (en) * 2008-01-07 2009-07-16 University Of Vermont And State Agricultural College Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer
EP2686008A1 (de) * 2011-03-15 2014-01-22 INSERM - Institut National de la Santé et de la Recherche Médicale Zusammensetzungen und verfahren zur hemmung der durch chemotherapieinduzierte seneszenz verursachten tumorentwicklung
JP2016502669A (ja) * 2012-12-07 2016-01-28 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 抗ｍｉｆ抗体細胞遊走アッセイ
JP7128827B2 (ja) * 2016-10-24 2022-08-31 エフ．ホフマン－ラ ロシュ アーゲー 固定分析物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5529898A (en) 1993-08-19 1996-06-25 Duke University Methods of detecting disorders of the central nervous system by detecting autoantibodies which specifically bind ionotropic glutamate receptors
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5459128A (en) * 1993-11-12 1995-10-17 Dana-Farber Cancer Institute Human monocyte chemoattractant protein-1 (MCP-1) derivatives
US6429289B1 (en) * 1994-06-23 2002-08-06 Massachusetts Institute Of Technology Class BI and CI scavenger receptors
US7245748B2 (en) * 1997-01-21 2007-07-17 Yeda Research And Development Co., Ltd. Apparatus for monitoring a system with time in space and method for diagnosing a condition of a prostate
US20020099040A1 (en) 1997-09-05 2002-07-25 Monty Krieger Sr-bi antagonists and use thereof as contraceptives and in the treatment of steroidal overproduction
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
US6087385A (en) * 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives
JP2001024194A (ja) 1999-05-06 2001-01-26 Toshiba Corp 半導体装置の製造方法及び半導体装置
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
US6420346B1 (en) 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
WO2001089565A1 (en) 2000-05-19 2001-11-29 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for reducing tumor growth and metastasis by inhibiting mcp-1 activity
EP1335741A4 (de) 2000-08-25 2005-10-26 Yeda Res & Dev METHODE ZUR PRÄVENTION VON AUTOIMMUNKRANKHEITEN MIT CpG-ENTHALTENDEN POLYNUCLEOTIDEN(04.03.02)
DE10051983A1 (de) 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
KR20020058151A (ko) * 2000-12-29 2002-07-12 박호군 집속이온빔을 이용하는 상온동작 단전자 터널링트랜지스터 제조방법
AU2001267804B2 (en) 2001-06-27 2007-05-31 Radiancy Inc. Acne treatment
ITBO20020459A1 (it) * 2002-07-17 2004-01-19 Pei Protezioni Elaborazioni Dispositivo di copertura e protezione per macchine di impianti
CA2496419A1 (en) 2002-08-19 2004-02-26 Abgenix, Inc. Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
US20040052790A1 (en) * 2002-09-18 2004-03-18 Advanced Biotherapy, Inc. Treatment of schizophrenia
US20090011974A1 (en) 2002-10-30 2009-01-08 Bocharov Alexander V Scavenger Receptor B1 (Cla-1) Targeting for the Treatment of Infection, Sepsis and Inflammation
WO2005025613A1 (en) 2003-03-12 2005-03-24 Rappaport Family Institute For Research In The Medical Sciences Methods of identifying biomolecular targets for diagnosis and therapy
EP1601682B1 (de) 2003-03-12 2008-05-07 Rappaport Family Institute For Research in the Medical Sciences Verbindungen und verfahren zur diagnose von prostatakrebs
DE602004016732D1 (de) 2003-03-12 2008-11-06 Rappaport Family Inst For Res Zusammensetzungen und verfahren zur diagnose und behandlung einer entzündung
US8017113B2 (en) 2003-03-12 2011-09-13 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
WO2005072113A2 (en) 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
JP4907117B2 (ja) 2004-08-30 2012-03-28 ルネサスエレクトロニクス株式会社 半導体装置

Also Published As

Publication number Publication date
EP1601682A4 (de) 2006-06-21
ATE394676T1 (de) 2008-05-15
US20060193863A1 (en) 2006-08-31
WO2004080273A3 (en) 2005-08-04
EP1601682A2 (de) 2005-12-07
WO2004080273A2 (en) 2004-09-23
US8486641B2 (en) 2013-07-16
US7749714B2 (en) 2010-07-06
US20100261210A1 (en) 2010-10-14
EP1601682B1 (de) 2008-05-07

Similar Documents

Publication Publication Date Title
DE59903915D1 (de) Verfahren zur frühen diagnose von carcinomen
WO2007109881A8 (en) Biomarkers useful for diagnosing prostate cancer, and methods thereof
WO2006036744A3 (en) Methods for a global assay of coagulation and fibrinolysis
DE60325617D1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
ATE551367T1 (de) Epha2-bindende antikörper und verfahren zu ihrer verwendung
EP2829881A3 (de) Diagnosemittel für Darmkrebs
DE602006006855D1 (de) Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb)
WO2006001931A3 (en) Prouroguanylin as therapeutic and diagnostic agents
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
HK1149956A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
DE602004013554D1 (de) Verbindungen und verfahren zur diagnose von prostatakrebs
DE60317484D1 (de) Verfahren und vorrichtung zur vorhersage von kardiovaskulären ereignissen
ATE422671T1 (de) Verfahren zur diagnose von morbus alzheimer
HK1080945A1 (en) Method of determining risk for prostate cancer recurrence
DE60317070D1 (de) Verfahren zur diagnose von multipler sklerose
ATE550668T1 (de) Verfahren zur identifizierung von patienten mit erhöhtem risiko für ein unerwünschtes herz- kreislauf-ereignis
WO2004094652A3 (en) Zinc-based screening test and kit for early diagnosis of prostate cancer
DE602004027534D1 (de) Diagnostische verfahren für therapeutische verbindungen sowie verfahren zur überwachung der azathioprin-therapie
DE60135918D1 (de) Gerät für prostatekrebsdiagnose
ATE483983T1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen
ATE429440T1 (de) Formen prostataspezifischer antigene und verfahren zu deren nachweis
EP1724579A3 (de) Verfahren zur Diagnose von Prostatakrebs und zur Analyse von Prostatatumoren
EP1636587A4 (de) Einen für menschliches protoonkogenes protein spezifischen antikörper enthaltender diagnostischer kit für leberzirrhose
DE69931644D1 (de) Verfahren zur diagnose, feststellung, einstufung, darstellung sowie behandlung gynäkologischer krebserkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition